[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-liver\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-liver":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100563846","retrolaminar-block-versus-subcostal-transversus-abdominis-plane-block-in-liver-resection-surgery-100563846",false,"NCT06621472","Retrolaminar Block Versus Subcostal Transversus Abdominis Plane Block in Liver Resection Surgery","Retrolaminar Block Versus Subcostal Transversus Abdominis Plane Block in Patients Undergoing Open Liver Resection Surgery","Inclusion Criteria:\n\nPhysical status American Society of Anesthesiologists (ASA)II, III. Body mass index (BMI): 20-35 kg\u002Fm2.\n\nExclusion Criteria:\n\nPatient refusal Physical status ASA IV BMI \\< 20 kg\u002Fm2 and \\>35 kg\u002Fm2 known sensitivity or contraindication to drug used in the study (local anesthetics, opioids).\n\nHistory of psychological disorders and\u002For chronic pain. Contraindication to regional anesthesia e.g., local sepsis, pre- existing peripheral neuropathies, and coagulopathy.\n\nSevere respiratory, cardiac disorders and renal disease.","ALL","18 Years","65 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","Adequate pain control improves postoperative outcomes and is imperative for enhanced recovery after surgery (ERAS) . Open liver resection surgery is associated with intraoperative blood loss, hypotension, coagulopathy, pulmonary complications, liver impairment, and renal impairment, making perioperative pain management challenging . Multimodal analgesic strategies employing regional techniques decrease postoperative pain and opioid consumption following liver resections. Thoracic epidural analgesia (TEA) is considered the 'gold standard' for open thoracic and abdominal surgical procedures .",[27],"Cancer Liver","RECRUITING","2026-03-16",{"date":31,"type":32},"2026-03-18","ACTUAL",{"date":34,"type":32},"2024-10-01",{"date":36,"type":21},"2026-06-01",{"name":38,"class":39},"Cairo University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100576525","phase-4-managing-hepatitis-b-hep-b-and-human-papilloma-virus-hpv-related-cancers-and-mental-health-100576525","NCT06786429","Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.","Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers Among Women of Childbearing Age, and Young Adults in Zimbabwe in the Context of Mental Health: a Multimodal, Multifaceted Approach.","Inclusion Criteria:\n\n* For the High school students' group:\n\nAll students aged 13 years and older, enrolled at the selected Mtshabezi and Matopo High Schools in the Gwanda and Matobo Rural Districts during the five-year period of the project are eligible to participate in the study.\n\nAbility to understand and respond to questions on the Youth Risk Behavior Scree questionnaire and PHQ-9 scale.\n\nRelevant history of HPV vaccine administration. Ability to obtain parental\u002Fguardian consent for participation.\n\n\\- For the women group: All women and young female adults thirteen to forty-five years old and requesting health services for prenatal, post-partum, family planning and other care during the five-year project period are eligible to participate.\n\nMust not have received Hep B and HPV vaccine in the past and have no known contraindications to either of these two vaccines.\n\nAre able to understand and respond to the PHQ-9 and Edinburgh Postnatal Depression scales.\n\nMust have a valid consent for participation in the study.\n\nExclusion Criteria:\n\n* males who are not enrolled in these participating High Schools.\n* children below the age of thirteen who are not enrolled in high schools and are not seeking prenatal, post-partum and family planning services at these selected health facilities during the project period.\n* Any eligible potential participant without a valid consent.\n* Any potential participant who is excluded by a doctor or midwife for a known contraindicating medical condition that can lead to potential harm to the participant or staff.\n\nAny potential participant who is unable to understand and respond to the questions being asked.\n\nParticipants with proof of prior vaccination will be excluded from this part of the study.",true,"13 Years","45 Years",{"count":52,"type":21},1800,[54],"PHASE4","Aim: The main goal of this observational study is to determine the prevalence of Human Papilloma Virus(HPV) infection, and Hepatitis B (Hep B) immunity amongst women of childbearing age 13 to 45 years) attending clinics at Mtshabezi Mission and Matobo clinic respectively; and assess behavioral risk factors of high school students at these catchment areas that can put them at risk for developing cancer of the cervix and liver.\n\nQuestion: Can screening for cancer, and vaccination against Hep B and HPV, and cognitive behavior intervention help in preventing related cancers amongst these groups of participants.",[57,58,59,60,27,61,62],"Hepatitis B","Human Papilloma Virus","Gall Stones (& [Calculus - Gall Bladder])","Mental Health Issue","Cancer of Cervix","Depression, Anxiety","NOT_YET_RECRUITING","2026-01-17",{"date":66,"type":32},"2026-01-21",{"date":68,"type":21},"2026-08-30",{"date":70,"type":21},"2031-12-30",{"name":72,"class":39},"Eunice Dube",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":79,"targetDuration":81,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":126,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":152},"100320510","synergy-ai-artificial-intelligence-based-precision-oncology-clinical-trial-matching-and-registry-100320510","NCT03452774","SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","Inclusion Criteria:\n\n* Pts with solid and hematological malignancies;\n* Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2\u002FNeu, Tumor mutational burden\u002Fload (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A\u002FB, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1\u002F2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA\u002FB\u002FC, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.\n\nThese biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform\n\n* Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and\u002For patient\n\nExclusion Criteria:\n\n* ECOG PS \\> 2;\n* Abnormal organ function;\n* Hospice enrollment",{"count":80,"type":21},50000,"36 Months","OBSERVATIONAL","International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.",[85,86,87,88,89,27,90,91,92,61,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125],"Cancer, Metastatic","Cancer","Cancer of Pancreas","Cancer of Liver","Cancer of Stomach","Cancer of Rectum","Cancer of Kidney","Cancer of Esophagus","Cancer of Colon","Cancer of Larynx","Cancer, Lung","Cancer, Breast","Cancer, Advanced","Cancer Prostate","Cancer of Neck","Cancer of Skin","Neuroendocrine Tumors","Carcinoma","Mismatch Repair Deficiency","BRCA Gene Rearrangement","Non Hodgkin Lymphoma","Leukemia","Non Small Cell Lung Cancer","Cholangiocarcinoma","Glioblastoma","Central Nervous System Tumor","Melanoma","Urothelial Carcinoma","Bladder Cancer","Ovarian Cancer","Endometrial Cancer","Testicular Cancer","Breast Cancer","COVID","Myelofibrosis","Myeloproliferative Neoplasm","Myeloproliferative Disorders","Follicular Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Myelodysplastic Syndromes",[127,128,129,130,131,132,133,134,135,136,137,138,139,140,141],"artificial intelligence","virtual tumor board","clinical trial","clinical trial matching","electronic medical record","machine learning","cost of care","targeted therapy","immunotherapy","precision medicine","precision oncology","cancer","value based care","real world data","data analytics","2025-10-25",{"date":144,"type":32},"2025-10-28",{"date":146,"type":32},"2018-01-01",{"date":148,"type":21},"2040-06",{"name":150,"class":151},"Massive Bio, Inc.","INDUSTRY",68]